Burkova E, Bakhno I
Biomolecules. 2025; 15(2).
PMID: 40001583
PMC: 11853650.
DOI: 10.3390/biom15020280.
Jayavelu N, Samaha H, Wimalasena S, Hoch A, Gygi J, Gabernet G
medRxiv. 2025; .
PMID: 39990570
PMC: 11844586.
DOI: 10.1101/2025.02.12.25322164.
Arias-Arias J, Monturiol-Gross L, Corrales-Aguilar E
BioTech (Basel). 2025; 14(1).
PMID: 39982277
PMC: 11843899.
DOI: 10.3390/biotech14010010.
Muminov M, Tsiferova N, Pshenichnov E, Ermatova K, Charishnikova O, Abdullaev A
Vaccines (Basel). 2025; 12(12.
PMID: 39772081
PMC: 11680381.
DOI: 10.3390/vaccines12121420.
Oliveira K, Almeida A, Silva C, Brito M, Ribeiro E
Infect Dis Rep. 2024; 16(6):1084-1097.
PMID: 39728010
PMC: 11675320.
DOI: 10.3390/idr16060088.
Structure and dynamics of the interaction of Delta and Omicron BA.1 SARS-CoV-2 variants with REGN10987 Fab reveal mechanism of antibody action.
Lyukmanova E, Pichkur E, Nolde D, Kocharovskaya M, Manuvera V, Shirokov D
Commun Biol. 2024; 7(1):1698.
PMID: 39719448
PMC: 11668877.
DOI: 10.1038/s42003-024-07422-9.
Reduced response to SARS-CoV-2 vaccination is associated with impaired immunoglobulin class switch recombination in SLE patients.
Montamat G, Meehan C, Bradford H, Yildirim R, Guimaraes F, Johnson M
Clin Exp Immunol. 2024; 219(1).
PMID: 39658056
PMC: 11773804.
DOI: 10.1093/cei/uxae119.
Convalescent plasma therapy for COVID-19 - Donor selection strategies and establishment of a plasma bank.
Kajova M, Khawaja T, Levonen I, Pietila J, Virtanen J, Pakkanen S
New Microbes New Infect. 2024; 62:101525.
PMID: 39584055
PMC: 11584594.
DOI: 10.1016/j.nmni.2024.101525.
Cross-Reactive Immune Response of Bovine Coronavirus Spike Glycoprotein to SARS-CoV-2 Variants of Concern.
Cossu C, Franceschi V, Di Lorenzo A, Bolli E, Minesso S, Cotti C
Int J Mol Sci. 2024; 25(21).
PMID: 39519062
PMC: 11546235.
DOI: 10.3390/ijms252111509.
IgG1 versus IgG3: influence of antibody-specificity and allotypic variance on virus neutralization efficacy.
Kallolimath S, Sun L, Palt R, Foderl-Hobenreich E, Hermle A, Voss L
Front Immunol. 2024; 15:1490515.
PMID: 39512357
PMC: 11540624.
DOI: 10.3389/fimmu.2024.1490515.
Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination.
Clark J, Hoxie I, Adelsberg D, Sapse I, Andreata-Santos R, Yong J
Cell Rep. 2024; 43(11):114922.
PMID: 39504245
PMC: 11804229.
DOI: 10.1016/j.celrep.2024.114922.
Engineered protein subunit COVID19 vaccine is as immunogenic as nanoparticles in mouse and hamster models.
Matthews M, Kim T, Kim K, Meshcheryakov V, Iha H, Tamai M
Sci Rep. 2024; 14(1):25528.
PMID: 39462119
PMC: 11512993.
DOI: 10.1038/s41598-024-76377-y.
Implementation of an Immunoassay Based on the MVA-T7pol-Expression System for Rapid Identification of Immunogenic SARS-CoV-2 Antigens: A Proof-of-Concept Study.
Kumar S, Nan L, Kalodimou G, Jany S, Freudenstein A, Brandmuller C
Int J Mol Sci. 2024; 25(20).
PMID: 39456680
PMC: 11508112.
DOI: 10.3390/ijms252010898.
Three doses of Sars-CoV-2 mRNA vaccine in older adults result in similar antibody responses but reduced cellular cytokine responses relative to younger adults.
Bredholt G, Saevik M, Soyland H, Ueland T, Zhou F, Pathirana R
Vaccine X. 2024; 20:100564.
PMID: 39403561
PMC: 11472110.
DOI: 10.1016/j.jvacx.2024.100564.
Optimization of Cellular Transduction by the HIV-Based Pseudovirus Platform with Pan-Coronavirus Spike Proteins.
Thimmiraju S, Villar M, Kimata J, Strych U, Bottazzi M, Hotez P
Viruses. 2024; 16(9.
PMID: 39339968
PMC: 11437443.
DOI: 10.3390/v16091492.
Evaluating Immunologic and Illness Outcomes of SARS-CoV-2 Infection in Vaccinated and Unvaccinated Children Aged ≥ 5 Years, in a Multisite Longitudinal Cohort.
Porter C, Lyski Z, Uhrlaub J, Ellingson K, Jeddy Z, Gwynn L
Diseases. 2024; 12(8).
PMID: 39195170
PMC: 11354143.
DOI: 10.3390/diseases12080171.
CD81 fusion alters SARS-CoV-2 Spike trafficking.
Cone A, Zhou Y, McNamara R, Eason A, Arias G, Landis J
mBio. 2024; 15(9):e0192224.
PMID: 39140770
PMC: 11389398.
DOI: 10.1128/mbio.01922-24.
Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer.
Mack P, Hsu C, Rodilla A, Gomez J, Cagan J, Huang Y
Vaccines (Basel). 2024; 12(7).
PMID: 39066351
PMC: 11281667.
DOI: 10.3390/vaccines12070713.
Protective Non-neutralizing anti-N-terminal Domain mAb Maintains Fc-mediated Function against SARS-COV-2 Variants up to BA.2.86-JN.1 with Superfluous In Vivo Protection against JN.1 Due to Attenuated Virulence.
Izadi A, Godzwon M, Soderlund Strand A, Schmidt T, Kumlien Georen S, Drosten C
J Immunol. 2024; 213(5):678-689.
PMID: 39018495
PMC: 11335326.
DOI: 10.4049/jimmunol.2300675.
SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020-2023.
Carreno J, Wagner A, Monahan B, Singh G, Floda D, Gonzalez-Reiche A
Nat Commun. 2024; 15(1):5847.
PMID: 38992013
PMC: 11239669.
DOI: 10.1038/s41467-024-50052-2.
